Financials

v3.24.1.1.u2
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 2,071,989 $ 3,483,501
Prepaid expenses and other current assets 371,212 382,273
Total current assets 2,443,201 3,865,774
Prepaid research and development expense 1,090,750 1,090,750
Operating lease right-of-use assets 9,811
Total assets 3,533,951 4,966,335
Current liabilities:    
Accounts payable and accrued expenses 781,846 1,475,667
Short-term notes payable 126,840 312,703
Operating lease liabilities - Current 9,811
Total liabilities 908,686 1,798,181
Shareholders’ equity:    
Preferred stock, no par value; 50,000,000 shares authorized; 5,417,000 and 5,417,000 Series A shares, 4,050,000 and 4,050,000 Series B shares, -0- and -0- Series C shares, 7,488,692 and 7,488,692 Series F shares outstanding at March 31, 2024 and December 31, 2023, respectively 1,592,723 1,592,723
Common stock, $0.001 par value; 350,000,000 shares authorized and 4,480,693 and 3,080,693 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively 4,480 3,081
Additional paid-in capital 209,697,149 207,790,604
Accumulated Deficit (208,669,087) (206,218,254)
Total shareholders’ equity 2,625,265 3,168,154
Total liabilities and shareholders’ equity $ 3,533,951 $ 4,966,335

Source

v3.24.1.1.u2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Grant revenue $ 17,024
Operating expenses:    
Research and development 663,414 1,672,576
General and administrative 1,796,689 1,249,263
Total operating expenses 2,460,103 2,921,839
Loss from operations (2,460,103) (2,904,815)
Other income (expense):    
Interest income 19,235 62,201
Interest expense (7,085) (3,347)
Other income 1,124
Foreign currency exchange, net (2,880)
Total other income, net 9,270 59,978
Loss before income taxes (2,450,833) (2,844,837)
Income tax benefit
Net loss $ (2,450,833) $ (2,844,837)
Basic net loss per share $ (0.70) $ (1.41)
Diluted net loss per share $ (0.70) $ (1.41)
Shares used to compute basic net loss per share 3,496,078 2,204,766
Shares used to compute diluted net loss per share 3,496,078 2,204,766

Source

v3.24.1.1.u2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash flows from operating activities:    
Net loss $ (2,450,833) $ (2,844,837)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 11,303
Stock-based compensation expense 69,344 79,966
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets 11,061 300,085
Operating lease right of use assets 9,811 48,716
Accounts payable and accrued expenses (693,821) 346,309
Change in operating lease liabilities (9,811) (50,237)
Net cash used in operating activities (3,064,249) (2,108,695)
Cash flows from financing activities:    
Payments on short-term notes payable (185,863) (159,750)
Net proceeds from issuance of common stock 1,838,600
Net cash provided by (used in) financing activities 1,652,737 (159,750)
Net decrease in cash and cash equivalents (1,411,512) (2,268,445)
Cash and cash equivalents at beginning of period 3,483,501 11,426,785
Cash and cash equivalents at end of period 2,071,989 9,158,340
Supplemental disclosure of cash flow information:    
Interest paid $ 7,085 $ 3,347

Source